DMAC DiaMedica Therapeutics, Inc.

2.200.03 (+1.38%)
IEX real time price: 12:32:23 PM

Quote

Previous Close
-
Day Range
-
52 Week Range
$1.70-$8.46
Volume
45,171
Avg Volume
39,643
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$26.42M
Enterprise Value (EV)
$9.26M
PE Ratio
-
EV/EBITDA
-1.45
Price/Sales
-
Price/Book
1.53
PEG Ratio
0.04

Financials

Revenue
-
Gross Profit
-
EBITDA
-$6.39M
EPS, ttm
-$0.81
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
11/26/2019 (42 days)
Debt to Equity
-
Debt
-
Cash
$16.82M
Net Debt
-

Performance

Beta
1.80
200 Day Moving Avg
$3.36
50 Day Moving Avg
$2.61
52 Week Change
-73.01%
YTD Change
-31.44%
1 Month Change
-23.59%
3 Month Change
-49.30%
6 Month Change
-39.72%
1 Year Change
-73.01%
2 Year Change
-63.41%
5 Year Change
-72.64%

Share Count

Shares Outstanding
12.0M
Float
8.7M
Restricted Shares
3.3M
Restricted Shares, %
27.78%

DiaMedica Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Rick John Pauls

Website: http://www.diamedica.com

Description: DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Employees: 9